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Objectives To examine sociodemographic predictors of self-reported screening attendance,
intention to accept human papillomavirus (HPV) testing and willingness to accept vaccination for a
daughter under 16.
Setting Home-based, computer-assisted interviews with a population representative sample of British
women.
Methods Participants were selected using random probability sampling of the Postcode Address
File, 994 women aged 25–64 were included in these analyses. Women reported their attendance
at cervical screening and intention to accept an HPV test. A subsample of those with a daughter
under 16 years (n ¼ 296) reported their willingness to accept HPV vaccination for their daughter.
Results Screening attendance was associated with education level (odds ratio [OR] ¼ 1.66,
conﬁdence interval [95% CI]: 1.07–2.56) and being married (OR ¼ 2.04, 95% CI: 1.37–3.03).
Acceptance of HPV testing was predicted by regular attendance for cervical screening
(OR ¼ 1.58, 95% CI: 1.03–2.42) and being from a white background (OR ¼ 2.20, 95% CI:
1.18–4.13). Daughter’s age was the only predictor of HPV vaccine acceptance, with mothers
whose youngest daughter was 13–16 years old being the most likely to accept vaccination
(OR ¼ 2.91, 95% CI: 1.27–6.65).
Conclusion In contrast to screening attendance, ethnicity plays an important role in HPV testing.
Speciﬁc cultural barriers should be identiﬁed and addressed to ensure ethnic disparities in testing
are limited. While marital status is associated with screening attendance, HPV testing could
overcome this bias. Sociodemographic variables seem to play a limited role in HPV vaccine
acceptance among mothers making vaccine decisions for their daughters, but as with other
studies, age of daughter is important. The scientiﬁc reasons for vaccinating at 12–13 years should
be emphasized in HPV information.
INTRODUCTION
I
n the UK there are around 2800 new cases of cervical
cancer each year, accounting for 1% of all cancers.
1
This low prevalence is largely due to the success of the
cervical screening programme, which has been estimated
to prevent around 80% of cervical cancer deaths.
2
However, cervical screening is not without costs; particularly
in relation to worry and discomfort associated with an
abnormal result.
3 There is also concern about socioeconomic
disparities in regular screening participation, which could be
contributing to differences in rates of cervical cancer.
1
Although some studies have failed to ﬁnd a consistent socio-
economic bias in self-reported screening attendance,
4 area-
level data show lower uptake in more socioeconomically
deprived health authorities.
5
The discovery that nearly all cases of cervical cancer are
caused by high-risk types of human papillomavirus (HPV),
a highly prevalent, sexually transmitted infection,
6 has
offered new opportunities for cervical cancer prevention.
HPV-DNA testing is used alongside cytology in the USA to
increase sensitivity, and ongoing research is assessing the
beneﬁt of HPV testing as part of primary screening in the
UK and Europe.
7 The use of HPV testing as a triage for
borderline changes and mild dyskaryosis is currently being
rolled out across the UK.
8 Qualitative research suggests
that many women will welcome the introduction of HPV
testing, although they are likely to have some concerns.
9
No large-scale quantitative studies of HPV testing acceptabil-
ity have been carried out in the UK.
The most dramatic development in prevention of cervical
cancer is prophylactic vaccination against the common high-
risk types of HPV (16 and 18) that are responsible for 70% of
cervical cancers. Phase III trials have demonstrated high efﬁ-
cacy in young women (15–26 years) who were not infected
with vaccine-related virus types at baseline.
10,11 In the USA,
the Centers for Disease Control and Prevention have rec-
ommended vaccination for women up to 26 years, and in
the UK, the Department of Health has announced that
they will be offering vaccination to girls aged 12–13 years
with a ‘catch-up’ programme for girls up to 18 years.
12
A number of studies have assessed intended acceptance of
HPV vaccination in the USA
13 and the UK,
14,15 but most of
these have been in speciﬁc population subgroups. In the two
UK studies, anticipated acceptance levels were 75–80%
among mothers considering the vaccine for their
daughters.
14,15
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to ensure informed participation in testing and vaccination
and therefore developing public information about HPV
will be an important target for health education.
Understanding the demographic characteristics associated
with acceptance of HPV testing and vaccination could help
identify groups that need to be targeted.
This study used data collected in a population-based
survey of British women aged 25–64 years, as part of an
‘omnibus survey’. We ﬁrst asked about cervical screening
uptake. Women were then given information about HPV
and asked about their likelihood of accepting an HPV test.
A subset of respondents with a daughter aged up to 16
years also reported their willingness to have their daughter
immunized against HPV. Sociodemographic factors, screen-
ing history, and usual sources of health information, were
considered as potential predictors of acceptance of testing
and vaccination.
METHODS
Participants
Data were collected by including questions in the NatCen
(National Centre for Social Research) omnibus survey
between November 2006 and February 2007. Addresses in
England, Scotland and Wales (n ¼ 6100, of which
n ¼ 5585 were eligible) were selected using stratiﬁed
random probability sampling of the Postcode Address File.
Face-to-face interviews were carried out at 2981 addresses.
The questions on HPV were asked only of female respon-
dents. NatCen abide by the Social Research Association
Ethical guidelines.
Materials and measures
At the beginning of the interview, women were asked about
attendance at cervical screening. They were asked to indicate
which statement was closest to their situation: ‘I regularly
have cervical cancer screening and do not need reminding’,
‘I regularly have cervical cancer screening but do need
reminding’, ‘I do not have regular cervical cancer screening
in spite of reminders to do so’ and ‘I have never had a cervi-
cal cancer screening test’. Women who responded with the
ﬁrst two options were coded as regular attenders.
Respondents were then given brief information about
HPV and cervical cancer and the potential availability of
testing and vaccination (the vaccine was mentioned as an
option for the future, because no announcement on vacci-
nation had been made in the UK). They were asked how
likely they would be to accept an HPV test if they were
offered one at their next cervical screening appointment,
with responses on a ﬁve-point scale (very unlikely, unlikely,
not sure, likely, very likely). Women with a daughter aged
up to 16 years old were also asked how willing they would
be to accept HPV vaccination for their daughter, with
responses on a 10-point scale from ‘not at all willing’ to
‘extremely willing’.
Sociodemographic factors including age, marital status,
ethnicity, education level and income were assessed by
asking respondents to place themselves in one of several
predeﬁned categories. These were combined to create appro-
priate group sizes for analysis. The proportion of ethnic
minorities in this sample was 6%, which is slightly lower
than the UK population rate (8%). This meant that
numbers were too small to examine differences between
ethnic minority groups, so respondents were categorized as
white (British, Irish or other backgrounds) and non-white
(mostly Asian/Asian British or Black/Black British
backgrounds).
To assess women’s sources of information on female
health issues, they were asked to select as many responses
as appropriate from a list (doctor/general practitioner,
gynaecologist, other specialist, nurse or pharmacist, leaﬂets
in doctor’s clinics, friends and relatives, media sources in-
cluding newspapers, magazines, television or radio, the
internet).
Analysis
Data were analysed using SPSS 14.0 (SPSS Inc., Chicago, IL)
and were weighted to account for number of adults in the
household and non-responder demographics. Because
responses to testing and vaccination were highly skewed
towards acceptance, outcomes were recoded into binary
variables. Respondents were allocated to one of two
groups for HPV testing and vaccination. Respondents who
reported being likely or very likely to accept an HPV test
were coded as ‘acceptors’, all other respondents were
coded as ‘hesitant’. The overall distribution for the
10-point scale of willingness to accept HPV vaccine for a
daughter is shown in Figure 1. Women who rated their will-
ingness as seven or above were considered to be ‘acceptors’
and all other respondents were coded as ‘hesitant’.
Univariate logistic regression analyses were used to identify
sociodemographic predictors of screening attendance and
intended acceptance of HPV testing and vaccination.
Signiﬁcant variables were also entered into a multivariate
logistic regression model. Analyses were repeated with
only those who responded ‘very likely’ as acceptors of HPV
testing and using 8, 9 and 10 as cut-off points for mothers
accepting HPV vaccine for a daughter. These additional ana-
lyses produced the same pattern of results with only very
small differences in the odds ratios (OR), indicating that
the results were not a function of the way that we categor-
ized acceptance.
RESULTS
Face-to-face interviews were carried out at 2981 addresses
(response rate ¼ 53.4%). For the purpose of this study
only data from women aged 25–64 were included
(n ¼ 994). The characteristics of the sample are shown in
Table 1.
Figure 1 This distribution of responses for willingness to vaccinate
daughter
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The majority of women in the screening age range reported
regular attendance at cervical screening (89%, n ¼ 866).
There were no differences in screening attendance on the
basis of age, ethnicity or reported income, but women
who were married or cohabiting were more likely to
attend for screening than those who were single
(OR ¼ 2.04, conﬁdence interval [95% CI]: 1.37–3.02).
There were also some differences by education level; with
women who had at least minimum educational qualiﬁca-
tions (GSCEs) being more likely to attend screening than
those with no qualiﬁcations (OR ¼ 1.81, 95% CI: 1.18–
2.79). Women who reported reading leaﬂets to ﬁnd out
about female health issues were more likely to attend cervi-
cal screening regularly than those who did not read leaﬂets
(OR ¼ 2.08, 95% CI: 1.38–3.15). When marital status,
education level and reading leaﬂets were entered into a
multivariate model, all three remained signiﬁcant predictors
of self-reported screening attendance (Table 2).
HPV testing
After reading a page of information about HPV, women were
asked about their willingness to accept an HPV test.
Respondents who said they were likely or very likely to
accept the test are described as ‘acceptors’ and the remaining
respondents are described as ‘hesitant.’ Overall, 70% were
accepting of HPV testing and 30% were hesitant about the
test. In univariate logistic regression analyses, screening
attendance, ethnicity and education were signiﬁcant predic-
tors of accepting an HPV test. Women who reported regular
attendance for cervical screening were more likely to accept
an HPV test (OR ¼ 2.01, 95% CI: 1.33–3.05). Women from
a white background (OR ¼ 2.66, 95% CI: 1.53–4.64) and
those with at least some educational qualiﬁcations
(OR ¼ 1.63, 95% CI: 1.17–2.27) were also more likely to
be ‘acceptors’. Women who reported using some common
sources of health information to ﬁnd out about female
health issues, including leaﬂets (OR ¼ 1.54, 95% CI:
1.15–2.06), friends (OR ¼ 1.48, 95% CI: 1.09–2.01) and
the media (OR ¼ 1.47, 95% CI: 1.09–1.97), were also
more likely to be ‘acceptors,’ but getting information from
health professionals made no difference to anticipated
acceptance. When these six variables were entered into a
multivariate model, screening attendance, ethnicity and
talking to friends about female health issues remained sig-
niﬁcant predictors of HPV test acceptance (Table 2).
HPVvaccination fordaughters
Women who had a daughter up to 16 years (n ¼ 296, 30%
see Table 1 for subsample characteristics) were included in
an additional analysis to assess maternal acceptance of
HPV vaccination for their daughter (Table 3). They were
asked to rate on a 10-point scale how willing they would
be to vaccinate their daughter against HPV. The mean
rating was 7.9 (standard deviation ¼ 3.1), the distribution
of responses is shown in Figure 1. Given that the distribution
was extremely skewed we deﬁned women who responded
seven or above as ‘acceptors’ of the vaccination (74%) and
the others as ‘hesitant’ (26%). Anticipated acceptance of
HPV vaccination for a daughter was not associated with
screening attendance, marital status, ethnicity, education
or income. The only variable associated with acceptance
was the age of the woman’s youngest daughter. Mothers
whose youngest daughter was 13–16 years were more
likely to be ‘acceptors’ of HPV vaccination than those with
younger daughters (OR ¼ 2.91, 95% CI: 1.27–6.65).
DISCUSSION
Over the past 20 years, cervical screening in the UK has been
highly successful, preventing thousands of cancers each
year. HPV testing and vaccination offer new opportunities
for cervical cancer prevention. As these are introduced into
the cancer prevention services in the UK, it will become
increasingly important to identify predictors of acceptance
of these new technologies. This study used a survey method-
ology to identify population groups who were most likely to
report screening attendance and intention to participate in
HPV testing or vaccination.
Self-reported screening uptake in this study was higher
than the UK ﬁgure for 2006 (89% compared with 79%).
16
This could be due to social desirability bias in response to
the screening question or because women who respond to
surveys may simply be more likely to ‘take part’ more gen-
erally, and therefore could be over-represented in the
sample. Marit
al status and education were signiﬁcant predictors of screen-
ing attendance – with more educated women and married
women being more likely to attend. This is consistent with
ﬁndings from a previous ONS survey (collected in 1999),
which also found marital status and education level to be
the two sociodemographic predictors of self-reported screen-
ing attendance in a multivariate model.
4
Regular attendance at cervical screening was an important
predictor of HPV test acceptance in both the univariate and
multivariate model. This could be because the question
Table1 Sample characteristics
All respondents
(n ¼ 994)
Subsample of
mothers (n ¼ 296)
%( n)% ( n)
Screening attendance
Do not attend 11.2 (110) 10.0 (30)
Regularly attend 88.8 (866) 90.0 (268)
Respondent age
25–34 years 24.6 (244) 29.9 (89)
35–44 years 29.0 (288) 53.4 (160)
45–54 years 24.2 (240) 14.8 (44)
55–64 years 22.3 (221) 1.8 (6)
Marital Status
Married/cohabiting 71.3 (708) 73.1 (219)
Single/separated/
divorced/widowed
28.7 (285) 26.9 (81)
Ethnicity
Non-white 6.1 (60) 10.2 (31)
White 93.9 (928) 89.8 (269)
Education
No qualiﬁcations 21.1 (209) 14.5 (43)
At least minimum
qualiﬁcations
78.9 (779) 85.5 (254)
Household income
Tertile 1 (lowest) 24.6 (244) 24.8 (74)
Tertile 2 29.9 (297) 39.1 (117)
Tertile 3 (highest) 32.1 (319) 27.0 (81)
Information sources used
Talking to health
professionals
79.7 (792) 82.0 (254)
Talking to friends 41.2 (409) 45.7 (137)
Leaﬂets 46.3 (460) 48.7 (146)
Media 53.1 (527) 52.6 (157)
Internet 35.1 (349) 37.7 (113)
Note: Because the data were weighed frequencies were not whole numbers, they have
therefore been rounded up to the nearest whole number.
Sociodemographic predictors of HPV testing and vaccination 93
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and it is possible that HPV self-testing could overcome this
barrier. Self-testing has been shown to be highly acceptable
among British women
17 and a recent study in Sweden
achieved 58% self-test return rate among women who
were not attending for conventional cervical screening.
18
There were two interesting differences between screening
attendance and intended acceptance of an HPV test. Firstly,
while ethnicity was not associated with reported screening
attendance, it was a predictor of HPV test acceptance, with
higher acceptance among respondents from white back-
grounds. This is consistent with qualitative work that has
identiﬁed speciﬁc cultural barriers to HPV testing among
women from some ethnic minority groups.
9 The second
difference is that marital status, which was associated with
reported screening attendance, was not important in relation
to HPV testing. Existing research suggests that women who
are single are less likely to attend for cervical screening.
4
This is worrying because single women are less likely to be
in a monogamous relationship and may therefore be at
higher risk of HPV and pre-cancerous changes. However
there was no association between marital status and HPV
test acceptance. One possible explanation for this is that
understanding the sexually transmitted nature of HPV and
cervical cancer could make detection methods more accepta-
ble to those in higher risk groups.
In this study we used a 10-point scale to assess acceptabil-
ity of HPV vaccination. The mean acceptability score was 7.9,
which was slightly higher than the mean score of 6.6 found
in a USA study using the same scale.
19 The data for the USA
study were collected in 2005 and so this small difference is
not unexpected. Previous surveys assessing HPV vaccine
acceptability in the UK have found that between 75% and
80% of parents are likely to accept the vaccine and our
survey ﬁndings identiﬁed 74% of parents selecting a rating
of seven or above in our 10-point scale.
There was a lack of association between sociodemographic
factors and acceptance of HPV vaccination among mothers,
and although we recognize that our subsample may have
been underpowered to detect small differences as signiﬁcant,
the ﬁndings are consistent with results from other surveys
assessing anticipated HPV vaccine acceptance in the
UK.
14,15 If HPV vaccine acceptance spans all sociodemo-
graphic groups, then it has the potential to decrease dispar-
ities in cervical cancer in the long term. Because screening
will need to continue in order to detect cervical cancers
caused by high-risk types other than HPV 16 and 18, there
are likely to be some persistent differences due to socioecon-
mic status (SES) differences in screening participation.
4,5 The
only signiﬁcant predictor of HPV vaccine acceptance was age
of youngest daughter, with mothers of 13–16 year olds
being most likely to accept vaccination for their daughter.
Daughter’s age has been highlighted as an important factor
in previous research,
20,21 and therefore, emphasizing the
importance of vaccinating at the recommended age (12–
13 years old) will be important to ensure administration of
the vaccine is not delayed.
Respondents who reported reading leaﬂets, using the
media, or talking to friends as sources of information for
ﬁnding out about female health were more likely to be
accepting of an HPV test. This may be indicative of an inter-
est in health issues more broadly. However, these factors
were not associated with acceptance of vaccination for a
daughter, which suggests that any campaign to promote vac-
cination may need to involve alternative methods of
communication.
One major limitation of this survey was that the response
rate, though adequate, was not high (53.4%). Given the
over-representation of screening attenders in the sample, it
is possible that the ﬁndings over-estimate the acceptability
of HPV testing and vaccination. The absolute levels of accept-
ability should therefore be interpreted with some caution.
However, unlike most previous surveys of HPV vaccine
acceptability, our questions formed part of a general
survey on a range of issues, so speciﬁc attitudes to this
topic are unlikely to have biased participation.
To our knowledge this is the ﬁrst study to use data from a
nationally representative British sample to examine the pre-
dictors of public interest in HPV testing and vaccination. The
results are consistent with ﬁndings from studies in the USA
13
and from speciﬁc populations in the UK,
14,15 which indicate
that acceptance is likely to be good even before any public
education campaigns. Sociodemographic factors predicted
acceptance of an HPV test, but there appeared to be less
association between SES and willingness to vaccinate a
daughter against HPV. Vaccinating young girls against HPV
may have the potential to reach groups that would be
Table 3 Predictorsofhumanpapillomavirusvaccineacceptance
for a daughter (mothers of upto16 year olds)
% likely to
Univariate model
accept P OR (95% CI)
Screening attendance
Do not attend 73.9 0.921 1.00
Regularly attend 73.1 1.05 (0.44–2.51)
Anticipated acceptance of HPV test
Hesitant about
accepting
73.3 0.830 1.00
Likely to accept 74.4 1.06 (0.61–1.84)
Respondent age
25–34 years 68.1 0.270 1.00
35–44 years 74.9 1.40 (0.76–2.56)
45–64 years 81.5 2.07 (0.82–5.22)
Age of youngest daughter
8 years or under 68.1 0.041 1.00
9–12 years 72.5 1.24 (0.66–2.30)
13–16 years 86.1 2.91 (1.27–6.65)
Marital status
Married/cohabiting 73.6 0.775 1.00
Single/separated/
divorced/widowed
75.1 1.09 (0.62–1.91)
Ethnicity
Non-white 60.5 0.103 1.00
White 75.5 2.01 (0.87–4.66)
Education
No qualiﬁcations 77.1 0.604 1.00
At least minimum
qualiﬁcations
73.2 0.81 (0.36–1.80)
Household income
Tertile 1 77.5 0.236 1.00
Tertile 2 76.9 0.71 (0.35–1.44)
Tertile 3 79.5 1.13 (0.52–2.47)
Information sources used
Talking to health professionals
No 82.4 0.140 1.00
Yes 72.2 0.56 (0.26–1.21)
Talking to friends
No 73.0 0.709 1.00
Yes 75.0 1.11 (0.64–1.93)
Leaﬂets
No 71.5 0.318 1.00
Yes 76.9 1.33 (0.76–2.33)
Media
No 70.6 0.242 1.00
Yes 77.0 1.39 (0.80–2.42)
Internet
No 71.7 0.726 1.00
Yes 77.7 1.38 (0.77–2.45)
OR, odds ratio; CI, conﬁdence interval
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in cervical cancer. Future work should continue to explore
this possibility in the context of actual vaccine uptake in
the years to come.
...............
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